I survived bird flu - this is what it's like: My whole skull was THROBBING
The virus, also known as H5N1, is currently spreading across the US and has reached the UK triggering global health chiefs today to warn of an impending pandemic.
At present the outbreak, which began in 2022, has affected hundred of millions of birds on farms across 50 US states and more than 1,000 dairy cow herds.
There have been 70 human cases in America, including one confirmed death—although these individuals are thought to have contracted the virus from animals.
Meanwhile in the UK, seven human cases of the H5N1 virus have been detected since 2021—the most recent in January this year.
Experts also expressed concern after the world's first case of bird flu in sheep was detected on a Yorkshire farm last month.
In an interview with The Telegraph last year, one of the few bird flu survivors to have spoken publicly raised the prospect that, as the virus continues to spread, that it could also transmit between people.
Nguyen Thanh Hung, from Hanoi, contracted the virus during a bird flu outbreak that swept Southeast Asia in 2005—infecting 44 people and killing 32.
The car salesman who had a passion for long-distance running, then 42, fell ill after nursing his sick brother in hospital.
His ordeal began in December, when he attended the funeral of his brother's son, which was held during Tet, which is Vietnam's equivalent to Thanksgiving.
After the service Hung and his family had sat down to a meal of duck's blood soup, which is a local delicacy.
Two days later, his brother developed a headache and breathing problems, and was taken to hospital.
Hung rushed to his bedside, and stayed with him for the following five days as his condition steadily worsened.
Struggling to breathe, he was put into intensive care, and given oxygen.
Yet his brother kept on removing the oxygen mask, forcing Hung to lean across his body to replace it. 'I was about 30cm from his face,' he told writer Mark Honigsbaum, who tracked him down.
Hung's brother lost his fight on January 9 and just days later, Hung also began suffering symptoms.
X-rays revealed 'an ominous white shadow' on his lung and, when his temperature soared, he was admitted to the same hospital his brother died in.
'My whole skull was throbbing. I felt like I was going colour blind and the walls were pressing in on me,' recalled Hung.
Lab tests then confirmed he had contracted H5N1—as had his late brother.
'I was quite scared at first, but by then I was starting to feel better,' he said. 'The fever and pain were over and I thought to myself, 'I'm through the worst'.
Despite this, it was another ten days before Hung was well enough to be discharged.
It is unclear exactly how he picked up the virus. It could have been the raw ducks blood soup—however Hung insists he barely touched it.
More worrying is the possibility that he picked it up while nursing his brother in hospital, as it would provide proof the infection transmits from human to human.
Also in 2005, an 11 year old Thai girl transmitted the disease to her mother and aunt, according to reports in the British Medical Journal.
There is currently no evidence the disease is spreading between people.
However experts have recently warned that the virus could be mutating to become more transmissible to humans.
Professor Susan Hopkins, chief medical adviser at UKHSA, said in January, after the first confirmed human case in England: 'The risk of avian flu to the general public remains very low despite this case.
'We have robust systems in place to detect cases early and take necessary action, as we know that spillover infections from birds to humans may occur.
'Currently there is no evidence of onwards transmission.
'People are reminded not to touch sick or dead birds and it's important that they follow Defra advice about reporting any suspected avian influenza cases.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
2 hours ago
- Telegraph
Men not seeking support until cancer is incurable
Too many men are seeking support with cancer only when it has become incurable, a charity has said. Maggie's, the cancer support charity, gave its backing to The Telegraph's campaign for targeted prostate cancer screening. Its experts said on Monday that although men made up about half the cancer diagnoses in the UK, they were much more likely than women to end up seeking support for the disease when it was incurable. Maggie's 24 centres across the UK provide help for those with all types of cancer, with around one third of visits from men. But of men who do seek support, 37 per cent are living with incurable cancer, compared with 31 per cent of women, new data show. The charity said the imbalance suggests men are much more likely to delay seeking help and only present with more advanced symptoms. It added that this could, in part, be due to men being diagnosed only when their cancer has already spread, a trend which could be addressed by routine screening. Health advisers are currently considering the evidence for the introduction of such screening, which could mean tests being offered to those with an increased risk of the disease. Maggie's, which was founded by Maggie Keswick Jencks – a writer, gardener and designer who wanted to create a better place for people to receive support after her own experiences when diagnosed with breast cancer – said its centres mostly see men with cancer at a later stage, presenting with more significant side-effects, particularly prostate cancer treatment side-effects. These range from mood changes and hot flushes to muscle loss, erectile dysfunction and incontinence. Dame Laura Lee, chief executive of Maggie's, said: 'Detecting cancer earlier means it is easier to treat, and people can avoid some of the more gruelling side-effects that come with aggressive treatments. 'Prostate cancer, despite being the most common form of the disease in the UK for men, also has one of the highest survival rates of any cancer when detected early enough. 'That's why we welcome The Telegraph's campaign to ensure more men have access to screening and are able to receive effective treatment quickly if cancer is detected.' Maggie's offers free support from diagnosis through treatment and beyond, with the charity urging men reluctant to seek help to visit a centre to meet expert staff and access emotional and practical support for themselves and families. Centres run specialist sessions including support groups, prehabilitation, rehab programmes and hormone‑ therapy workshops tailored for men undergoing androgen deprivation therapy (ADT ) Dame Laura added: 'Maggie's is here for people with cancer at any stage, from the moment of diagnosis, throughout treatment and beyond, and we urge men who may be reluctant to seek support to drop in to one of our centres and speak to our expert staff about how we can help you, as well as your family and friends. 'To keep up with demand for our emotional and practical support, we are rapidly expanding our sessions for men with cancer, so please do come into your nearest centre for support.' Research suggests that men tend to delay seeking help because of emotional barriers. A survey found 42 per cent of men living with cancer had not asked for support. Among them, 21 per cent cited unwillingness to talk about feelings and 14 per cent felt embarrassment about seeking help. The findings come as thousands of fundraisers gear up to take on the cycling challenge Tour de 4 on Sept 7. The event is organised by Sir Chris Hoy, whose openness about his own incurable prostate cancer diagnosis has prompted thousands more men to get symptoms checked, with almost 5,000 more NHS referrals for urological cancer.
Telegraph
a day ago
- Telegraph
Huge 22-inch rat found in home
An enormous 22-inch rat, thought to be the UK's biggest, has been captured at a home in the north of England. The rodent was discovered in a property in the Normanby area of Redcar and Cleveland by a pest controller. Conservative councillors have blamed the Labour-run council for the supersize pest, as they no longer handle domestic rat infestations and expect residents to foot the bill themselves. It comes as Birmingham has been plagued by rats because of growing mountains of uncollected waste amid a months-long bin strike. The crisis reached the point where officials in England's second city introduced a new 'rat tax' for locals if they call out council pest controllers. Glasgow was also hit with a rat crisis in 2023 when giant rats the size of 'small dogs' turned a street in the city into a no-go zone for refuse workers. The biggest rat on record to have been caught in Britain was by a Bournemouth rat catcher in 2018. It measured 21 inches from snout to tail. It is understood that the huge rat in Normanby was nesting in the property at the time. Cllr Taylor, who was sent the image by a local constituent, claimed that the rat 'was almost the size of a small cat'. 'The rats are getting more brazen everywhere now. It seems they have settled into the neighbourhood,' he told The Telegraph. 'I have dealt with rats in the past; it's certainly the biggest I've seen. It's a big concern that it was found in someone's home.' Cllr David Taylor has now urged the Labour-run council to take urgent action to tackle the problem and called for a full vermin study to be carried out across the borough, as well as joint action involving businesses, landlords and social housing providers. He warned: 'The longer this is ignored, the worse it will get. It is a growing problem.' It is estimated that there could be around 250 million rats in the UK, and they can carry illnesses which can be passed to humans, including Weil's disease, which has flu-like symptoms initially but can lead to jaundice and kidney failure. A Redcar and Cleveland council spokesman said: 'The council has a dedicated pest control officer who manages pest issues on council-owned land. 'While we no longer provide a wider pest control service, we do offer advice to residents where possible. 'The council continues to work with Beyond Housing, Northumbrian Water and other partners to address complex issues and explore potential solutions. 'There is also helpful guidance and preventative measures on our website to support people in dealing with pests.'
Telegraph
2 days ago
- Telegraph
World first as life-saving cancer drugs to be mixed at patients' bedsides
Cancer patients will get personalised drugs made at their bedside under new laws, The Telegraph can reveal. The UK is the first country in the world to relax the strict manufacturing rules that cause delays to time-sensitive treatments. An increasing number of new medicines, including for cancer and rare genetic disorders, involve creating a bespoke drug for each patient by collecting their cells and modifying them in a laboratory, before they are injected back into the patient. But because the samples have to be taken and edited in specialist facilities – often hundreds of miles away – patients are too often facing delays. They may become too unwell to receive the drug, or the medicine itself may not survive the journey because of its short shelf-life. From now, the last of these steps can be completed closer to the patient, reducing the time it takes to produce a life-saving treatment from months to just days, the medical regulator said. 'Flexible, responsive system' The new laws, introduced by the Medicines and Healthcare products Regulatory Agency (MHRA), will mean the drugs can be manufactured where the patient is – and given to them in hospital or their own homes. Writing in The Telegraph, Lawrence Tallon, the new chief executive of the MHRA, said it was about creating 'a more flexible, responsive system that meets the needs of modern medicine' rather than forcing 'the medicine to fit an outdated system'. 'Some of these advanced therapies are made using a person's own cells. Others are built around their genetic code. A few are so sensitive they can't be frozen or stored – they have to be given to the patient within mere minutes of being made. That's a world away from how medicines are typically mass-made and distributed today,' he said. 'In these cases, delays can be critical. Some patients have become too unwell to receive their treatment in time. In others, the medicine simply didn't survive the journey.' He added: 'Hospitals can now carry out the final steps of manufacturing on-site – under the same strict standards, but far more quickly. 'That means a cancer patient could now have their immune cells collected, modified, and returned at the same hospital. A child with a rare genetic disorder can receive a therapy made at their bedside.' 'Personalised therapies' Mobile units will also be deployed to finish the manufacturing of the drugs for patients who are too sick to leave their homes or need to limit hospital visits because of weakened immune systems. The MHRA said the move mirrored how chemotherapy and antibiotics are prepared locally, but stressed that there would still be strict safeguards and regulatory protocols. There will also be a 'central control site' that will oversee the personalised therapies being completed in hospitals. Wes Streeting, the Health Secretary, said it was a 'game-changer'. 'Cancer treatments tailored in days, not months. Life-saving therapies made at your bedside, not hundreds of miles away,' he said. 'Our Plan for Change promised to build an NHS fit for the future. Today we're delivering on that pledge by bringing cutting-edge care directly to patients when they need it most. 'This type of therapy means patients can be treated and return home more quickly.' One example of a personalised treatment that is set to become more accessible for patients is CAR-T cancer therapy. It involves genetically modifying a blood cancer patients' immune cells so that the immune system recognises and kills the cancer cells that would otherwise go undetected by the body and continue to spread. Previously, hospitals were only able to offer these treatments through complicated, one-off arrangements. The changes have already come into effect after the legislation, known as The Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations 2025, was passed last month. It covers a range of innovations, including cell and gene therapies, tissue-engineered treatments, 3D printed products, blood products, and medicinal gases. Lord Vallance, the science minister and Government's former chief scientific officer, said the 'world-first framework gives the NHS and innovators a clear, safe way to bring advanced treatments from the lab to the patient's bedside'. 'It's a powerful example of how smart regulation can help more patients benefit from the best of British science.' 'Modern medicine needs a modern delivery system' By Lawrence Tallon For most medicines, the system works well enough. Medicines are made in bulk, boxed up, and shipped off to where they're needed in the world. It's how care has been delivered for decades. But a new generation of personalised therapies is beginning to challenge that model – and unless we adapt, patients could miss out. Some of these advanced therapies are made using a person's own cells. Others are built around their genetic code. A few are so sensitive they can't be frozen or stored – they have to be given to the patient within mere minutes of being made. That's a world away from how medicines are typically mass-made and distributed today. In these cases, delays can be critical. Some patients have become too unwell to receive their treatment in time. In others, the medicine simply didn't survive the journey. We need a more flexible, responsive system that meets the needs of modern medicine, not force the medicine to fit an outdated system. That's why this week, the UK became the first country in the world to introduce a new legal framework that allows these advanced medicines to be made at the point of care. Under new regulations introduced by the Medicines and Healthcare products Regulatory Agency (MHRA), hospitals can now carry out the final steps of manufacturing on-site – under the same strict standards, but far more quickly. That means a cancer patient could now have their immune cells collected, modified and returned at the same hospital. A child with a rare genetic disorder can receive a therapy made at their bedside. No more shipping cells hundreds of miles away and hoping they survive the journey back. It also offers a safer alternative for people too unwell to travel, or whose immune systems make hospital visits risky. 'Supporting early access to promising treatments' This is part of a wider effort to modernise the way we support innovation in the UK. We've shortened the time it takes to approve clinical trials to 40 days. We've introduced new routes for authorising medicines already approved by trusted international regulators. And where the evidence is strong and the need is urgent, we support early access to promising treatments. We're paying particular attention to rare diseases, where patients often face the longest waits for new treatments. While each condition may affect only a few people, the overall impact is large: around 3.5 million people in the UK, and an estimated 300 million globally, live with a rare condition. Yet developing treatments is often more difficult, with fewer clinical trial participants and less commercial return. That's why we're offering targeted support. For companies working on rare disease therapies, we've reduced or waived fees and increased access to expert scientific advice. The aim is to make it simpler and more affordable to bring forward safe treatments where there is high need and few other options. We're also supporting smarter ways to generate evidence. For very rare conditions, large-scale trials aren't always possible. We're working with researchers to use high-quality real-world data, like NHS records and patient registries, so that safe and effective treatments aren't held back for lack of traditional trial data. Medical innovation doesn't end with discovery or what's in the vial. It's also about tackling the barriers that stop new treatments reaching patients. That means creating a safe system built for tomorrow's medicines – especially for people with the fewest options – whether by changing how they're approved, how trials are run, or how evidence is gathered. After all, a life-changing treatment only matters because we can deliver it when and where the person needs it.
